6533b7d9fe1ef96bd126d4d4
RESEARCH PRODUCT
Mitomycin C bei oberflächlichen Hornhautablationen mit dem Excimer-Laser: Eigene Erfahrungen und Literaturübersicht
H B DickUlrike Kottlersubject
medicine.medical_specialtygenetic structuresbusiness.industryMitomycin CVisual rehabilitationCorneal opacityeye diseasesCorneal transparencySurgeryOphthalmologyPharmacotherapyCorneal surgerySubepithelial fibrosisMedicinesense organsMajor complicationbusinessdescription
Haze formation with loss of corneal transparency and surface irregularities and myopic regression are the major complications after corneal refractive surface surgery. The use of mitomycin C (MMC) with its antibiotic and antineoplastic properties is intended to inhibit wound healing mechanisms leading to subepithelial fibrosis. We report the use of MMC to achieve visual rehabilitation in the re-treatment of 3 eyes of 2 patients following refractive corneal surgery. According to the literature, the local use of MMC 0.02 % for 2 minutes is safe and enables one to treat and prevent stromal haze and myopic regression and allows a reduction of the postoperative topical pharmacotherapy. Results are still limited due to small case numbers and short follow-up periods.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2005-06-01 | Klinische Monatsblätter für Augenheilkunde |